Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Olezarsen sodium may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
Tryngolza is a medicine that changes the way in which the body breaks down fats (a so-called lipidlowering medicine). It contains the active substance olezarsen. It is used together with dietary restrictions to help treat people aged 18 years and above with familial chylomicronemia syndrome (FCS). FCS is an inherited disease that gives rise to abnormally high levels of fats called triglycerides in the blood. This can lead to inflammation of the pancreas, causing severe pain, lasting damage to the pancreas, and can be life threatening. Olezarsen works by blocking the production of the molecule that slows the removal of triglycerides. By doing so, it helps to lower the levels of triglycerides in the blood and can help to reduce the occurrence of acute pancreatitis (inflammation of the pancreas). You will only be given Tryngolza if genetic testing has confirmed you have FCS. Tryngolza may be given after you have already received other medicines used to lower the levels of triglycerides in blood and have maintained a low fat diet without having much effect. 2.
e Tryngolza
Do not use Tryngolza
1
Warnings and precautions Talk to your doctor, pharmacist or nurse before using Tryngolza if you have any of the following medical problems:
Tryngolza
Always use this medicine exactly as your doctor, pharmacist or nurse has told you. Check with your doctor or pharmacist if you are not sure. You should continue the very low-fat diet that your doctor has recommended during treatment with Tryngolza. The recommended dose is 80 mg once a month; the dose should be given on the same day each month. Tryngolza should be injected under the skin (subcutaneous administration) of your belly (abdomen), the front of your upper legs, or the back of your upper arms. You or your caregiver will be trained how to use Tryngolza according to the instructions for use provided at the end of this leaflet. When injecting this medicine yourself, you can only inject it under the skin of your belly or upper legs. Only a healthcare provider or caregiver may give you an injection in the back of your upper arm.
2
Each single-dose pre-filled pen of this medicine gives you a dose of 80 mg in 0.8 mL. The pen can only be used once and should be disposed after use. Before using this medicine, it is important that you read, understand, and closely follow the instructions for use provided at the end of this leaflet. Do not use this medicine if the solution appears frozen, is cloudy, or contains particles; it should be a clear and colourless to yellow liquid. You may see air bubbles in the solution, this is normal. Do not inject:
Like all medicines, this medicine can cause side effects, although not everybody gets them. Serious side effects Common (may affect up to 1 in 10 people) If you get any of the following side effects, contact your doctor immediately:
Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine. 5.
Tryngolza
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and pre-filled pen label after 'EXP'. The expiry date refers to the last day of that month. Store in a refrigerator (2 °C – 8 °C). Store in the original package in order to protect from light. Tryngolza can also be stored in the original package outside the refrigerator (up to 30 °C) for up to 6 weeks. If storing Tryngolza outside the refrigerator, write the disposal date on the outer carton. The disposal date is maximally 6 weeks after taking the medicine out of the refrigerator, and should be noted in the space indicated for storage up to 30 °C. If the expiry date on the pre-filled pen label or disposal date on the carton has passed, do not use the pre-filled pen and discard it. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6.
What Tryngolza contains
INSTRUCTIONS FOR USE Tryngolza is an injection given under the skin with a disposable single-dose pre-filled pen. Do not use Tryngolza until you completely understand the procedure described below. If you have any questions about how to use Tryngolza, please contact your doctor, pharmacist or nurse.
Plunger
Single-dose pre-filled pen
Viewing window Medicine Clear cap Orange needle shield
Other supplies (not included) Alcohol wipe
Cotton ball or gauze
5
Sharps container
Small bandage
Get ready to inject Tryngolza Step 1 Remove from the refrigerator a) Remove the pre-filled pen from the refrigerator (2 °C – 8 °C). b) Keep the pre-filled pen in the original carton and let the pre-filled pen reach room temperature (up to 30 °C) for 30 minutes before injecting. Do not try to speed up the warming process using other heat sources, such as a microwave or hot water. If you store Tryngolza outside the refrigerator, write the disposal date on the outer carton. The disposal date is maximally 6 weeks after you take the medicine out of the refrigerator, and should be noted in the space indicated for storage up to 30 °C. Step 2 Inspect the medicine a) Check the expiry ('EXP') date. Do not use Tryngolza if the 'EXP' date or disposal date on the carton has passed. b) Check the medicine through the viewing window. The medicine should be a clear and colorless to yellow liquid. There should be no particles. It is normal to see air bubbles in the solution. Do not use the pre-filled pen if:
• • • •
the clear cap is missing or not attached. the expiry ('EXP') date or disposal date has passed. the medicine looks frozen, cloudy, or has particles. the pre-filled pen appears damaged.
6
Step 3 Choose the injection site a) Choose an injection site on the stomach or the front of the thigh. b) Only caregivers may inject in the back of upper arm. Do not inject:
• • •
within 2 inches (5 cm) of the belly button. into skin that is bruised, tender, red, or hard. into scars or damaged skin.
For all
stomach
thigh
Step 4 Wash hands and clean the injection site The person administering the injection should: a) Wash their hands with soap and water. b) Clean the injection site with an alcohol wipe in a circular motion. Let the skin air dry. Do not touch the cleaned skin before injecting. Injecting Tryngolza Step 5 Remove and throw away the clear cap a) Hold the pre-filled pen by the middle with the clear cap facing away from you. b) Remove the clear cap by pulling it straight off. Do not twist it off. The needle is inside the orange needle shield. c) Throw away the clear cap in the trash or sharps container. Do not remove the clear cap until right before you inject. Do not recap the pre-filled pen. Do not push the orange needle shield against the hand or finger.
7
For caregivers only
back of the upper arm
Step 6 Begin injection a) Hold the pre-filled pen in one hand. Place the orange needle shield at a 90-degree angle against your skin. Make sure you can see the viewing window. b) Push firmly and hold the pre-filled pen straight against the skin. You will hear a click as the injection starts. You may hear a second click. This is normal. The procedure is not finished. c) Hold the pre-filled pen against the skin for 10 seconds to make sure the full dose has been given. Do not move, turn, or change the angle of the pre-filled pen during the injection. Step 7 Finish injection a) Check that the orange plunger rod has moved down to fill the entire viewing window. If the orange plunger rod does not fill the viewing window, you may not have received the full dose. If this happens or if you have other concerns, contact your healthcare provider. b) Remove the pre-filled pen by lifting it straight up. After removal from the skin, the orange needle shield locks into place and covers the needle. c) There may be a small amount of blood or liquid where you injected. This is normal. If needed, press a cotton ball or gauze on the area and apply a small bandage. Do not reuse the pre-filled pen.
8
Throwing away Tryngolza Step 8 Throw away the pre-filled pen Put the used pre-filled pen in a sharps container right away after use. Do not throw away the pre-filled pen in your household waste. Do not recycle your used sharps disposal container. Do not reuse the pre-filled pen or clear cap. If you do not have a sharps container, you may use a household container that is:
• • • • •
made of a heavy-duty plastic, can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out, upright and stable during use, leak-resistant, and properly labelled to warn of hazardous waste inside the container.
When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be local laws about how you should throw away used pre-filled pens. Ask your phamacist or see your local public health government website (where available) for more details on how you should dispose of sharps in your location.
9
Tryngolza 80 mg Solution for injection in pre-filled pen comes as injection containing 80mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Tryngolza 80 mg Solution for injection in pre-filled pen is olezarsen sodium.
This leaflet reproduces the patient information leaflet approved for Tryngolza 80 mg Solution for injection in pre-filled pen, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Tryngolza is indicated as an adjunct to diet in adult patients for the treatment of genetically confirmed familial chylomicronemia syndrome (FCS).
Posology
The recommended dose of olezarsen is 80 mg administered by subcutaneous injection once monthly.
Missed dose
If a dose is missed, Tryngolza should be administered as soon as possible. Dosing at monthly intervals should be resumed from the date of the most recently administered dose.
Special populations
Elderly population
No dose adjustment is required in patients ≥ 65 years of age (see section 5.2).
Renal impairment
No dose adjustment is necessary in patients with mild or moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 to < 90 mL/min/1.73 m2) (see section 5.2).
Olezarsen has not been studied in patients with severe renal impairment or end-stage renal disease and should only be used in these patients if the anticipated clinical benefit outweighs the risk.
Hepatic impairment
No dose adjustment is necessary in patients with mild hepatic impairment (total bilirubin ≤ upper limit of normal [ULN] with aspartate aminotransferase [AST] > ULN, or total bilirubin > 1-1.5 × ULN with any AST) (see section 5.2).
Olezarsen has not been studied in patients with moderate or severe hepatic impairment and should only be used in these patients if the anticipated clinical benefit outweighs the risk.
Paediatric population
The safety and efficacy of this medicinal product in children and adolescents below 18 years of age have not yet been established. No data are available (see section 5.1).
Method of administration
This medicinal product is intended for subcutaneous use only. It should not be administered intramuscularly.
Each pre-filled pen is for single use only.
Patients and/or caregivers should be trained in the administration of this medicinal product in accordance with the comprehensive instructions for use provided at the end of the package leaflet.
This medicinal product should be administered into the abdomen or front of the thigh. The back of the upper arm can also be used as an injection site if a healthcare provider or caregiver administers the injection. It should not be injected into skin that is bruised, tender, red, or hard, into scars or damaged skin; the area around the navel should be avoided.
Some patients might not be responsive to the treatment after 6 months, in such a case the discontinuation of olezarsen should be considered on an individual basis by the prescribing physician.
For instructions on handling of the medicinal product before administration, see section 6.6.
Ηypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Hypersensitivity reactions
Hypersensitivity reactions (including symptoms of diffuse erythema and chills) have been reported in patients treated with Tryngolza (see section 4.8). If a serious hypersensitivity reaction occurs, Tryngolza must be discontinued immediately and appropriate therapy initiated.
General
Limited safety data exist for olezarsen use in FCS patients at the time of marketing authorisation. While no serious risks of thrombocytopenia, hepatotoxicity, or renal toxicity were identified during clinical development, these adverse reactions have been observed with some antisense oligonucleotides and cannot be completely excluded.
Use in patients with low platelet counts
Some patients with FCS are susceptible to platelet count variability over time as part of the natural history and progression of the disease. There are limited data available on the use of olezarsen in FCS patients with platelet count < 100 000/mm3.
Excipient with known effect
Sodium
This medicinal product contains less than 1 mmol sodium (23 mg) per 80 mg dose, that is to say essentially 'sodium-free'.
No interaction studies have been performed.
In vitro studies show that olezarsen is not a substrate or inhibitor of transporters, does not interact with highly plasma protein bound medicines, and is not an inhibitor or inducer of cytochrome P450 (CYP) enzymes. Oligonucleotide therapeutics, including olezarsen, are not typically substrates of CYP enzymes. Therefore, olezarsen is not expected to cause or be affected by interactions mediated through transporters, plasma protein binding or CYP enzymes.
Tryngolza can be used with other lipid-lowering medicines, for example statins and fibrates.
Pregnancy
There are no data from the use of olezarsen in pregnant women.
Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).
As a precautionary measure, it is preferable to avoid the use of Tryngolza during pregnancy and women of child-bearing potential should practice effective contraception.
Breast-feeding
There is no information on the excretion of olezarsen/metabolites in human milk, the effects of olezarsen on breastfed newborns/infants, or the effects of olezarsen on milk production in treated women (see section 5.3).
The unconjugated antisense oligonucleotide (ASO), which shares the same nucleotide sequence but lacks N-acetylgalactosamine (GalNAc), was present in the milk of lactating mice at very low levels. Oligonucleotide-based products typically have poor oral bioavailability. Due to the poor oral bioavailability of this medicinal product, it is considered unlikely that low levels present in human milk will lead to clinically relevant levels in breastfed newborns/infants.
A risk to the newborns/infants cannot be excluded.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Fertility
No clinical data on the effect of this medicinal product on human fertility are available.
No adverse effects of olezarsen on fertility were seen in mice (see section 5.3).
Olezarsen has no or negligible influence on the ability to drive and use machines.
Summary of the safety profile
In patients with FCS, the most commonly reported adverse reactions during treatment with olezarsen were injection site erythema (17%), headache (16%), arthralgia (15%), and vomiting (10%).
Tabulated list of adverse reactions
The safety data described below reflects exposure to olezarsen in 89 patients with FCS in clinical trials who received at least one dose of olezarsen. Of these, 77 patients received at least 6 months of treatment and 65 patients received at least 12 months of treatment. The mean duration of treatment for these patients was 521 days (range: 28 to 1 080 days).
Adverse reactions are listed according to MedDRA system organ class. The frequency of adverse reactions is defined using the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1 000 to < 1/100); rare (≥ 1/10 000 to < 1/1 000); very rare (< 1/10 000); and not known (cannot be estimated from available data). Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.
Table 1: Adverse reactions
System organ class
Very common
Common
Immune system disorders
Hypersensitivity
Nervous system disorders
Headache
Gastrointestinal disorders
Vomiting
Musculoskeletal and connective tissue disorders
Arthralgia
Myalgia
General disorders and administration site conditions
Injection site erythema
Injection site discolouration
Chills
Injection site pain
Injection site swelling
Description of selected adverse reactions
Hypersensitivity
Hypersensitivity has been observed with olezarsen. Severe hypersensitivity reactions (including symptoms of bronchospasm, diffuse erythema, facial swelling, urticaria, chills, and myalgias) have been observed in 2 patients in clinical trials. In both patients the event was acute, required treatment, and resulted in treatment discontinuation.
Injection site reactions
Injection site reactions occurred in olezarsen-treated patients with FCS. These local reactions were mostly mild and consisted of injection site erythema (17%), discolouration (9%), pain (6%), and swelling (5%). These events are either self-limiting or can usually be managed using symptomatic treatment.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
In the case of overdose, patients should be carefully observed and supportive care administered, as appropriate.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Tryngolza 80 mg Solution for injection in pre-filled pen. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.